30 closest matches · ranked by relevance
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma · Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14
Lymphoma
Primary: Assessment of Tumor Response — 30.3; 54.5 percentage of participants
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Lymphoma
Primary: Time to Rituximab Failure (TTRF) — 3.92; 4.32; 1.39; 4.83 years — p=0.33
Lymphoma, Non-Hodgkin
Primary: Complete Remission (CR) Rate of Induction Therapy After Cycle 6 (28 Days) (FAS) — 24.5 percentage of participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Ann Arbor Stage III Grade 1 Follicular Lymphoma · Ann Arbor Stage III Grade 2 Follicular Lymphoma · Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma
Primary: Number of Participants With Best Overall Disease Response — 0; 56; 17; 8 Participants
Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma
Primary: Percentage of Participants With Complete Response (CR) at End of Treatment Period — 31; 25 percentage of participants
Lymphoma · Mantle Cell Lymphoma · Indolent Lymphoma
Primary: Progression-free Survival at 2 Years — 15 Participants
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lymphoma, Mantle-Cell
Primary: Maximum Tolerated Dose — 2.24 mg/m^2
Diffuse Large B-Cell Lymphoma
Primary: Overall Response (OR) Rate — 36 Participants
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
Lymphoma, Non-Hodgkin
Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…
Low-grade B Cell Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
Primary: Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) — 67.8; 70.0; 68.1 percentage…
Lymphoma
Primary: Percentage of Participants With Indolent NHL Achieving CR or Partial Response (PR) According to International Response Criteria for NHL — 66.7 Percentage of Participants
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
Primary: Overall Response Rate — 12 Participants — p=0.044
Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory
Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants
Relapsed Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…
Marginal Zone Lymphoma · B-cell Lymphoma
Primary: ORR (Overall Response Rate) — 46 Percentage of Participants
Ann Arbor Stage II Follicular Lymphoma · Ann Arbor Stage II Marginal Zone Lymphoma · Ann Arbor Stage III Follicular Lymphoma
Primary: Progression Free Survival (PFS) — 71.2; 54.2 percentage of participants
B-cell Lymphoma · Indolent B-cell Lymphoma
Primary: Determine Complete Response Rate (CRR) of Increased Dose Rituximab in Indolent B-cell Lymphomas — 21 Participants
Follicular Lymphoma · Small Lymphocytic Lymphoma · Lymphoplasmacytic Lymphoma
Primary: Overall Response Rate — 57.6 percentage of participants — p=< 0.0001
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma · Recurrent Grade 1 Follicular Lymphoma
Primary: Proportion of Responses (Complete Response or Partial Response) — 19.0; 42.9 percentage of participants
Lymphoma
Primary: Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population — 49.64; 54.77 Months — p=0.5167
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…